ASCO: Novel Agent Promising in Pretreated Myeloma (CME/CE)

(MedPage Today) -- Phase II trial shows 18-month median survival with isatuximab
Source: MedPage Today State Required CME - Category: Consumer Health News Source Type: news
More News: Health | Myeloma